ArticleScientific reports2026
Efficacy of fully covered self-expanding metal stents removal versus stent-in-stent techniques in recurrent malignant distal biliary obstruction.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Fully covered self-expandable metal stents (FCSEMSs) are widely used in managing malignant distal biliary obstruction (MDBO). However, recurrent biliary obstruction (RBO) has become a significant challenge due to improved patient survival with advanced chemotherapy. This multicenter retrospective cohort study evaluated revision techniques for FCSEMS dysfunction in 159 patients with MDBO initially treated with FCSEMSs. Patients were categorized into four groups based on the revision method: stent exchange with self-expandable metal stents (SEMS, n = 53) or plastic stents (n = 23), and stent-in-stent placement with SEMS (n = 51) or plastic stents (n = 32). All procedures achieved 100% technical and clinical success. The primary time to recurrent biliary obstruction (TRBO) showed no significant difference among the groups (mean: 148 days, 95% confidence interval [CI]: 127-170 days). However, secondary TRBO differed significantly (p = 0.014): 161 days (SEMS, stent exchange), 53 days (plastic stent, stent exchange), 104 days (SEMS, stent-in-stent), and 67 days (plastic stent, stent-in-stent). Multivariate analysis revealed that stent-in-stent placement with SEMS increased the risk of RBO compared to SEMS stent exchange (hazard ratio [HR]: 6.53, 95% CI: 1.89-22.55, p = 0.003). Additionally, revision within 180 days was associated with a higher risk of RBO (HR: 1.77, 95% CI: 1.10-2.86, p = 0.019). Overall survival was comparable across all groups. These findings suggest that SEMS stent exchange after FCSEMS removal is an effective revision method for RBO in MDBO, providing improved secondary stent patency without increasing adverse events or affecting overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.